Fetal Growth Restriction & Maternal Cardiovascular Risk
To determine whether or not women with a history of having a baby with intrauterine growth retardation (IUGR) was more likely to have risk factors for cardiovascular disease versus women with a pregnancy not complicated by IUGR.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Fetal Growth Restriction & Maternal Cardiovascular Risk|
- Blood pressure [ Time Frame: 4 to 12 years after pregnancy ] [ Designated as safety issue: No ]
- Triglycerides and LDL cholesterol [ Time Frame: 4 to 12 years after pregnancy ] [ Designated as safety issue: No ]
- Glucose [ Time Frame: 4 to 12 years after pregnancy ] [ Designated as safety issue: No ]
|Study Start Date:||August 2005|
|Study Completion Date:||April 2009|
|Primary Completion Date:||April 2009 (Final data collection date for primary outcome measure)|
Intrauterine growth restriction leads to major neonatal morbidity and mortality. Moreover, recent birth registry studies have suggested that women bearing IUGR babies may have an elevated risk of cardiovascular disease.
This cohort study tested whether exposed women, with a previous intrauterine growth restriction (IUGR) baby, versus unexposed women, with a pregnancy not complicated by IUGR, had elevations in markers of cardiovascular risk. Exposure was defined among a geographically defined cohort as having had a singleton baby in the < 5 %tile of weight for gestational age, in the absence of pre-pregnancy diabetes., hypertension, renal disease, or hypertension in pregnancy; controls had a singleton in the > 20%tile. Four to twelve years postpartum, women were assessed for multiple markers of cardiovascular risk, including blood pressure, lipids, adiposity, glucose and insulin, homocysteine and folate, markers of inflammation, markers of endothelial function, markers of angiogenesis, and markers of vascular function. Data analysis consisted of ANOVA and ANCOVA analyses comparing the outcomes of cardiovascular markers among exposed and unexposed women.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00241683
|Principal Investigator:||Roberta B. Ness, MD, MPH||The University of Texas Health Science Center, Houston|